MIRA Pharmaceuticals Announces Launch of Phase 2a Clinical Trial for Ketamir-2 After Demonstrating Superior Efficacy in Neuropathic Pain Models
Mira Pharmaceuticals Inc. has announced that its lead drug candidate, Ketamir-2, has demonstrated superior efficacy in preclinical neuropathic pain models compared to ketamine, gabapentin, and pregabalin. The findings, which have been accepted for publication in the journal Frontiers in Pharmacology, show that Ketamir-2 effectively restored sensory function and reversed pain behaviors. These results support Mira Pharmaceuticals' plan to submit a Phase 2a clinical trial protocol to the FDA by the fourth quarter of 2025, with the aim of initiating the study by year-end. Additionally, the company is exploring the potential of Ketamir-2 in other central nervous system indications, such as depression and anxiety. The global neuropathic pain market is projected to grow significantly, with North America accounting for a substantial share of the market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023110), on August 12, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。